Cancer

MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR Act

PLANEGG and MUNICH, GERMANY / ACCESSWIRE / March 22, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced the receipt of U.S.…

4 months ago

SciSparc: MitoCareX Unveils Groundbreaking Discovery of Small Molecule Structure in Anti-Cancer Research

MitoCareX Bio dedicates efforts to creating a predictive AI model to predict small molecules more efficiently TEL AVIV, Israel, March…

4 months ago

NextCure Provides Business Update and Reports Full Year 2023 Financial Results

Prioritizing and focusing on highest-value opportunities NC410 (ovarian and CRC) and LNCB74 (B7-H4 ADC)Based on early evidence of clinical activity…

4 months ago

LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments

-- Three Clinical Trials Currently Underway for Treating Ovarian, Lung and Sarcoma Cancers -- PASADENA, Calif., March 21, 2024 (GLOBE…

4 months ago

CMR Surgical announces over 20,000 surgical cases completed using Versius

Over 20,000 surgical cases completed using Versius The versatile surgical robot Versius has now been used to perform over 20,000…

4 months ago

Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma

Achieves critical first step toward priority review voucherBASKING RIDGE, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq:…

4 months ago

CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors

SOUTH SAN FRANCISCO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field…

4 months ago

Tonix Pharmaceuticals Announces Poster Presentation Describing Discovery of Novel Next-Generation Oxytocin Analogues at the American Chemistry Society (ACS) Spring 2024 Meeting

Four Phase 2 investigator-initiated studies of TNX-1900 (intranasal potentiated oxytocin) are ongoing for pediatric obesity, binge eating disorder, bone health…

4 months ago

Context Therapeutics Reports Full Year 2023 Operating and Financial Results

CTIM-76 IND filing on track for late March 2024 Cash and cash equivalents of $14.4 million as of December 31,…

4 months ago

Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023

Figure 1 Dose escalation and subject numbers by dose since initiating the trial in March 2023 PYX-201 Phase 1 Part…

4 months ago